Abbvie 1Q Revenues: $8.6 billion (+ 10%) 1Q Earnings: $3.0 billion (+23%) Comments: Global HUMIRA revenues were $4.7 billion, up 6%, with U.S. revenues of $3.7 billion, an increase of 14%, and international sales of $1.0 billion, down 15% due to biosimilar competition. Global revenues from the hematologic oncology portfolio were $1.5 billion, up 32%, with IMBRUVICA revenues of $1.2 billion, up 21%. Global VENCLEXTA revenues were $317 million. SKYRIZI revenues were $300 million and RINVOQ reve...